Joseph Tuscano
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (NCT04578600) | Joseph Tuscano | 2020-10-23 |
Track Joseph Tuscano automatically
Every clearance here is in the API, with alerts when new ones post.